Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
5.9% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
31
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
21
users have liked this narrative
12
users have commented on this narrative
27
users have followed this narrative
12 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
7
users have commented on this narrative
25
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
44.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Insight Molecular Diagnostics
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Rising Global Organ Transplants Will Drive Diagnostic Testing Expansion
Key Takeaways Expanding clinical adoption and demographic trends are set to boost recurring revenue and gross margins through increased testing volume and broader market penetration. Strategic focus on high-margin digital PCR kits and new partnerships diversifies income sources, enhances profitability, and lessens dependence on external financing.
View narrative
US$5.42
FV
52.2% undervalued
intrinsic discount
32.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
25 days ago
author updated this narrative
GoPro
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Diversified Supply Chain And New Products Will Transform Digital Imaging
Key Takeaways GoPro's strategic innovations and cost reductions are expected to enhance profitability and net margins, despite market challenges and competition. New product launches and subscription service enhancements aim to drive long-term revenue and earnings growth by improving technology leadership and recurring income streams.
View narrative
US$0.98
FV
22.8% overvalued
intrinsic discount
-0.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
25 days ago
author updated this narrative
Taysha Gene Therapies
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
FDA Meetings And TSHA-102 Trials Will Advance Approval
Key Takeaways Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence. Strategic alignment with regulatory and market priorities could enhance trial success, market adoption, and long-term revenue growth.
View narrative
US$8.32
FV
63.9% undervalued
intrinsic discount
123.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
25 days ago
author updated this narrative
AGF Management
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Tactical Alpha And Income Funds Will Shape Future Amid Uncertainty
Key Takeaways AUM growth and fund diversification in retail mutual and alternative products signal strong potential for future revenue expansion. Strategic acquisitions and a balanced capital allocation approach, including dividend increases, promise enhanced earnings and shareholder value.
View narrative
CA$13.92
FV
13.8% undervalued
intrinsic discount
4.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
25 days ago
author updated this narrative
Cantaloupe
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Launching Capital Micro Lending Service Will Help Small And Medium Businesses
Key Takeaways Growth in micro markets and Smart Stores, along with international expansion, is driving revenue through higher transaction volumes and new market entry. Initiatives like micro-lending, digital advertising, and product innovations contribute to enhanced profitability and address capital, marketing, and operational challenges.
View narrative
US$11.20
FV
2.9% undervalued
intrinsic discount
15.43%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
25 days ago
author updated this narrative
Vir Biotechnology
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
Key Takeaways ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams. Restructuring to reduce expenses and strategic capital allocation enhance financial stability, ensuring long-term sustainability and support for clinical development.
View narrative
US$17.63
FV
74.0% undervalued
intrinsic discount
40.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
25 days ago
author updated this narrative
Hackett Group
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Gen AI And SaaS Licensing Will Unlock Recurring Revenue
Key Takeaways Expanding AI-driven products, partnerships, and recurring revenue streams is set to accelerate growth, enhance margins, and increase pricing power. Investments in proprietary technology, client-focused innovation, and operational efficiency are driving stronger service delivery, larger pipelines, and improved earnings quality.
View narrative
US$28.33
FV
25.6% undervalued
intrinsic discount
2.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
4 days ago
author updated this narrative
Sleep Cycle
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities
Key Takeaways Strategic partnerships and technology licensing initiatives may diversify revenue streams and improve margins by leveraging Sleep Cycle's technology in various industries. Entry into the sleep apnea market and ongoing medical certifications could address significant unmet needs, potentially boosting revenue and earnings.
View narrative
SEK 44.75
FV
38.3% undervalued
intrinsic discount
14.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
Updated
narrative
Parex Resources
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Colombian Production Will Expand As Gas Monetization Unfolds
Key Takeaways Enhanced efficiency and cost reductions support resilient earnings and margins, strengthening the company's position amid changing oil prices and energy market dynamics. Expansion into new reserves, gas monetization, and a focus on low-emission operations drive growth, revenue diversification, and improved investor appeal.
View narrative
CA$17.00
FV
0.6% overvalued
intrinsic discount
0.61%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
27
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies